INDICATION AND USAGE Diclona™ is indicated for relief of pain associated with arthritis, backache, cramps, discomfort, neckache, soreness, sprains, strains.

It should be applied only to intact skin.

Sun avoidance is indicated during therapy.

WARNINGS Medicines intended to be applied to the skin should not be swallowed.

Diclona™ is flammable .

Keep away from open flame.

You should never heat, microwave, or add the medicine to hot water.

Risk of Methemoglobinemia Cases of methemoglobinemia have been reported in association with lidocaine use.

Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing the condition.

If lidocaine must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.

Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure and are characterized by a cyanotic skin discoloration and/or abnormal coloration of the blood.

Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death.

Risk of Serious Cardiovascular Events Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.

This risk may occur early in treatment and may increase with duration of use.

Fetal Toxicity Avoid use of NSAIDs in pregnant women at about 30 weeks gestation and later.

NSAIDs increase the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age.

Use of NSAIDs at about 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some case, neonatal renal impairment.

If NSAID treatment is necessary between about 20 weeks and 30 weeks gestation, limit Diclona Gel use to the lowest effective dose and shortest duration possible.

Serious Skin Reactions Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported in patients taking NSAIDs such as Diclona Gel.

DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling.

Heart Failure and Edema The Coxib and traditional NSAID Trialists’ Collaboration meta-analysis of randomized controlled trials demonstrated an approximately two-fold increase in hospitalizations for heart failure in COX-2 selective-treated patients and nonselective NSAID-treated patients compared to placebo-treated patients.

Avoid the use of Diclona Gel in patients with severe heart failure unless benefits are expected to outweigh the risk of worsening heart failure.

If Diclona Gel is used in patients with severe heart failure, monitor patients for signs of worsening heart failure.

ADVERSE REACTIONS Application Site Reactions During or immediately after treatment with Diclona™, the skin at the site of application may develop blisters, bruising, burning sensation, depigmentation, dermatitis, discoloration, edema, erythema, exfoliation, irritation, papules, petechia, pruritus, vesicles, or may be the locus of abnormal sensation.

These reactions are generally mild and transient, resolving spontaneously within a few minutes to hours.

Other Adverse Events Due to the nature and limitation of spontaneous reports in post marketing surveillance, causality has not been established for additional reported adverse events including: Asthenia, confusion, disorientation, dizziness, headache, hyperesthesia, hypoesthesia, lightheadedness, metallic taste, nausea, nervousness, pain exacerbated, paresthesia, somnolence, taste alteration, vomiting, visual disturbances such as blurred vision, flushing, tinnitus, and tremor.

Systemic (Dose-Related) Reactions Systemic adverse reactions following appropriate use of Diclona™ are unlikely, due to the small dose absorbed (see CLINICAL PHARMACOLOGY, Pharmacokinetics).

Systemic adverse effects of lidocaine is similar in nature to those observed with other amide local anesthetic agents, including CNS excitation and/or depression (light headedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest).

Excitatory CNS reactions may be brief or not occur at all, in which case the first manifestation may be drowsiness merging into unconsciousness.

Cardiovascular manifestations may include bradycardia, hypotension and cardiovascular collapse leading to arrest.